272 related articles for article (PubMed ID: 28731449)
21. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
22. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia.
Das S; Goossens J; Jacobs D; Dewit N; Pijnenburg YAL; In 't Veld SGJG; Teunissen CE; Vanmechelen E
Alzheimers Res Ther; 2023 Mar; 15(1):62. PubMed ID: 36964594
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
25. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
26. Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.
Boström G; Freyhult E; Virhammar J; Alcolea D; Tumani H; Otto M; Brundin RM; Kilander L; Löwenmark M; Giedraitis V; Lleó A; von Arnim CAF; Kultima K; Ingelsson M
J Alzheimers Dis; 2021; 81(2):629-640. PubMed ID: 33814444
[TBL] [Abstract][Full Text] [Related]
27. Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.
Morenas-Rodríguez E; Cervera-Carles L; Vilaplana E; Alcolea D; Carmona-Iragui M; Dols-Icardo O; Ribosa-Nogué R; Muñoz-Llahuna L; Sala I; Belén Sánchez-Saudinós M; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2016; 50(2):539-46. PubMed ID: 26682689
[TBL] [Abstract][Full Text] [Related]
28. Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures.
Falgàs N; Ruiz-Peris M; Pérez-Millan A; Sala-Llonch R; Antonell A; Balasa M; Borrego-Écija S; Ramos-Campoy O; Augé JM; Castellví M; Tort-Merino A; Olives J; Fernández-Villullas G; Blennow K; Zetterberg H; Bargalló N; Lladó A; Sánchez-Valle R
Hum Brain Mapp; 2020 Jun; 41(8):2004-2013. PubMed ID: 31944489
[TBL] [Abstract][Full Text] [Related]
29. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
[TBL] [Abstract][Full Text] [Related]
30. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
31. A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer's disease and mild cognitive impairment.
Mavroudis IA; Petridis F; Chatzikonstantinou S; Kazis D
Aging Clin Exp Res; 2020 Sep; 32(9):1639-1646. PubMed ID: 31463927
[TBL] [Abstract][Full Text] [Related]
32. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
[TBL] [Abstract][Full Text] [Related]
34. Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Dulewicz M; Kulczyńska-Przybik A; Mroczko B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33172069
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study.
Thordardottir S; Almkvist O; Johansson C; Zetterberg H; Blennow K; Graff C
J Alzheimers Dis; 2020; 76(3):941-953. PubMed ID: 32568193
[TBL] [Abstract][Full Text] [Related]
37. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study.
Ewers M; Mattsson N; Minthon L; Molinuevo JL; Antonell A; Popp J; Jessen F; Herukka SK; Soininen H; Maetzler W; Leyhe T; Bürger K; Taniguchi M; Urakami K; Lista S; Dubois B; Blennow K; Hampel H
Alzheimers Dement; 2015 Nov; 11(11):1306-15. PubMed ID: 25804998
[TBL] [Abstract][Full Text] [Related]
38. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease.
Baldacci F; Toschi N; Lista S; Zetterberg H; Blennow K; Kilimann I; Teipel S; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Bonuccelli U; Hampel H
Alzheimers Dement; 2017 Sep; 13(9):993-1003. PubMed ID: 28263742
[TBL] [Abstract][Full Text] [Related]
39. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
[TBL] [Abstract][Full Text] [Related]
40. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
